Morris Jackson, MD
Urology · Louisville, KYNPI 1477511921
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by Medtronic at 37.4% of the total.
Across 238 payments — averaging $31.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Endo Pharmaceuticals Inc.$1K
- Endo USA, Inc.$457
- Sumitomo Pharma America, Inc.$445
- Astellas Pharma US Inc$278
- AbbVie$266
- plus $2K from 30 others
What the payments were for
- Food & beverage$7,34298%
- Education$1522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 46 | $2,800 |
| Endo Pharmaceuticals Inc. | 54 | $1,139 |
| Endo USA, Inc. | 20 | $457 |
| Sumitomo Pharma America, Inc. | 24 | $445 |
| Astellas Pharma US Inc | 12 | $278 |
| AbbVie(2 entities) | 13 | $266 |
| Blue Earth Diagnostics | 5 | $211 |
| Baxter Healthcare | 2 | $206 |
| Merck | 5 | $181 |
| Urogen Pharma, Inc. | 3 | $165 |
| Neotract Inc. | 1 | $129 |
| Novartis | 5 | $126 |
| Siemens Medical Solutions USA, Inc. | 1 | $117 |
| Ferring Pharmaceuticals Inc. | 6 | $116 |
| Antares Pharma, Inc. | 6 | $95 |
| Teleflex LLC | 1 | $94 |
| Procept Biorobotics Corporation | 2 | $93 |
| AstraZeneca | 3 | $72 |
| Johnson & Johnson | 4 | $52 |
| Axonics, Inc. | 3 | $49 |
| Urovant Sciences Inc | 3 | $47 |
| Tolmar, Inc. | 2 | $40 |
| Pfizer | 2 | $39 |
| Myriad Genetic Laboratories, Inc. | 2 | $34 |
| Boston Scientific | 1 | $31 |
| Coloplast | 2 | $26 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $25 |
| Accord Healthcare, Inc. | 1 | $25 |
| Verity Pharmaceuticals Inc. | 1 | $24 |
| Myovant Sciences Inc. | 1 | $24 |
| Hollister Incorporated | 1 | $21 |
| Olympus America Inc. | 1 | $18 |
| Progenics Pharmaceuticals, Inc. | 1 | $15 |
| Immunitybio, Inc. | 1 | $14 |
| Pacira Pharmaceuticals Incorporated | 1 | $12 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,495 in reported general payments places this provider in the 80th percentile of 139 urology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 210 | $134,117 |
| MyrbetriqMirabegron | 102 | $99,307 |
| Chorionic GonadotropinChorionic Gonadotropin, Human | 14 | $14,089 |
| Tamsulosin Hcl | 816 | $10,265 |
| Testosterone | 23 | $7,726 |
| Testosterone Cypionate | 103 | $7,421 |
| Silodosin | 85 | $6,061 |
| Potassium Citrate ErPotassium Citrate | 73 | $5,379 |
| Estradiol | 63 | $4,499 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 165 | $3,074 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 121 | $2,575 |
| Finasteride | 216 | $2,410 |
| Oxybutynin Chloride ErOxybutynin Chloride | 72 | $1,925 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 81 | $464 |
| Ondansetron OdtOndansetron | 62 | $410 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $445 | $134,117210 claims |
| Astellas Pharma US IncMyrbetriq | $278 | $99,307102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 139 urology providers in Kentucky.
Other urology in Louisville
- Uzoma AneleLouisville$60K
- Kellen ChoiLouisville$17K
- Rosa ParkLouisville$16K
- Mohammed SaidLouisville$11K
- Terrance BlackfordLouisville$10K
- Jessica SchardeinLouisville$9K
- Jonathan WittenLouisville$9K
- Thomas SlabaughLexington$102K
- Lee EvansHopkinsville$56K
- Patrick HensleyLexington$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.